The therapeutic response to interferon was assessed according to the following criteria:
Complete response: elimination of HBsAg, HBeAg and HBV-DNA from the serum and return to normal of alanine aminotransferase (ALT) activity, at least until completion of the follow up period (six months).
Partial response: elimination of HBeAg and HBV-DNA, while HBsAg persisted, and return to normal of ALT activity at least until completion of the follow up period (six months).
No response: no change or transient loss of HBV-DNA and decrease in HBeAg titre.
STATISTICAL ANALYSIS
The therapeutic response was evaluated by the x2 test (p<0 05). The biochemical and virological results were analysed by the Wilcoxon's rank sum test.
Results
In the treatment group, one patient showed a complete response and eight patients a partial response (Table I) . Three patients in the control group spontaneously lost HBeAg and HBV-DNA and seroconverted to anti-HBe. The difference between the groups was significant at the p<O05 level.
The baseline HBV-DNA serum values in the group of patients who successfully responded to treatment (n=9) were significantly lower than in non-responders (Table II) . There was no correlation between therapeutic response and the following parameters: age, enzyme activities of aspartate aminotransferase (AST), ALT, -y-glutamyltransferase (GGT), alkaline phosphatase (ALP), glutamate dehydrogenase (GLDH), cholinesterase (CHE), concentrations of bilirubin and immunoglobulins, electrophoresis, duration of disease, and the patients' recollection of their acute viral hepatitis.
The loss of HBV-DNA was associated with a return to normal of serum transaminase activity. Reactivation of liver inflammation after seroconversion was not observed during 24 months of follow up.
The interferon was generally well tolerated. Initially, all treated patients showed mild flu like symptoms but, in most, these symptoms disappeared after the third injection of interferon.
Conclusions
The results show that 3 MU of interferon three times weekly over a period of four months can produce a positive response in 32% of patients with chronic HBV, compared with a spontaneous remission rate of 11% in untreated controls. These response rates are comparable with the results of other studies, which have been performed with various types of interferon in different dose regimens and with different treatment durations. 1-5 
